$380 million. That is what Medtronic has agreed to pay up front for Contego Medical, a privately held device maker whose carotid stent system sits in the narrow space between open surgery and standard stenting.
The deal also carries undisclosed payments tied to future performance, Medtronic said, and is expected to close in the third quarter of its fiscal 2027. Contego’s investors were not identified in the announcement, and Medtronic did not disclose the revenue the business generates today. It also did not say how many patients have been treated with the device since its first clearance.
The asset Medtronic is buying is a single delivery system. Contego’s Neuroguard IEP packs three components into one device: a nitinol stent, a post-dilation balloon and a 40-micron embolic filter meant to catch debris before it reaches the brain.
The Direct version of that system is designed for transcarotid artery revascularization, or TCAR, a procedure in which a catheter is placed directly into the carotid artery in the neck rather than threaded up from the groin. Contego describes its device as the only one that combines flow reversal with integrated embolic protection, and Medtronic’s own materials lean on that distinction.
The clinical claim rests on one study. In PERFORMANCE III, the company reported zero strokes and zero heart attacks among patients at 30 days. That is a strong result for a procedure performed on arteries that feed the brain, though it comes from a single trial with a modest number of patients rather than from a broad registry.
The deal has been building for years. Medtronic took a minority stake in Contego in 2020, then signed an exclusive distribution agreement in 2025 alongside an option to buy the company outright. Exercising that option converts a commercial relationship into ownership without the usual auction.
The strategic logic is competitive. Boston Scientific paid $1.16 billion for Silk Road Medical in 2024, buying the company that built the transcarotid market and its dedicated stent and neuroprotection system. Medtronic, the larger player in neurovascular devices overall, could not leave that segment to a rival.
Carotid disease is a slow-moving market with a stable patient base. Roughly one in five strokes is linked to a narrowed carotid artery, and treatment has split for two decades between surgery, which is durable but invasive, and stenting, which is less invasive but carries a higher risk of debris reaching the brain. A device that reduces that risk narrows the gap.
Medtronic already sells stent retrievers and other tools used to treat strokes once they happen. Buying a prevention device moves it earlier in the patient’s path, where reimbursement is more predictable and volumes are larger.
Price is the open question. Recent neurovascular tuck-ins have changed hands at multiples of revenue that vary widely, which limits the read-across from one deal to the next. At $380 million, the deal is small enough to fall below the threshold that would require a separate line in Medtronic’s guidance, and small enough that the company can absorb a disappointment. Analysts said the multiple implied by the purchase depends on payments that were not disclosed, which makes any comparison with the Boston Scientific deal imprecise.
For Contego’s backers, the payout caps a long stretch of private ownership in a category where exit routes are few. Device acquisitions of this size are usually about a single product with a cleared indication, not a platform, and buyers pay for the clinical data as much as for the hardware.
Regulatory risk sits mostly on the label. Medtronic will need to keep the device’s indications intact as it moves the product through its own quality systems, and any expansion of the treated population would require new trials. Physician training is the other constraint: transcarotid procedures require a different skill set from femoral access, and adoption has been gradual wherever the technique has launched.
Hospital economics matter too. Newer carotid devices are reimbursed through existing procedure codes, which means the company has to win on outcomes and ease of use rather than on a higher payment. That favors a device that shortens the procedure and reduces the need for a separate filter.
The transaction is one of several small device deals this year, as large manufacturers spend cash on tuck-ins rather than on large mergers. Strategics have been willing to pay for cleared products with clinical data attached, and sellers have been willing to accept staged payments to bridge the valuation gap.
Medtronic’s shares moved little on the announcement, which is the market’s way of saying the sum is immaterial to earnings and interesting only as a signal about where the company intends to compete. What happens next depends on the closing, on the first full year of Medtronic-led sales, and on whether Boston Scientific answers with a product of its own.


